Health-Related QOL Persists With Nivolumab Plus Cabozantinib Vs Sunitinib for First-Line RCC

Jennifer E. Engen

Long-term follow-up of the CheckMate 9ER trial (NCT03141177) that were presented at the 2022 Genitourinary Cancers Symposium demonstrated greater health-related quality of life (QOL) benefits with nivolumab (Opdivo) plus cabozantinib (Cabometyx) vs sunitinib (Sutent) for patients with advanced renal cell carcinoma, and these effects were seem across various definitions of […]